Answers are grounded in this paper and cite their sources.
In the United States, the efficacy and safety of convalescent plasma for treating coronavirus disease 2019 (COVID-19) is currently being tested in randomized placebo-controlled clinical trials. Treatment of individual patients with COVID-19 with convalescent plasma outside such trials is also now permitted through U.S. Food and Drug Administration Emergency Use Authorization. Here, members of the National Institutes of Health COVID-19 Treatment Guidelines Panel provide their views regarding use of convalescent plasma for treating COVID-19.
No takes yet. Share an insight, caveat, or question.
Pau et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: